Austin, Cynthia A

HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, MA. They are dedicated to revolutionizing the development of immunotherapies by utilizing their unique high-resolution translational platform, DIS, which provides an unprecedented understanding of immune dysregulation at the single cell level. Their goal is to enhance the probability of success for immunotherapies and improve patient outcomes through single-cell precision. With a focus on single cell science, HiFiBiO Therapeutics applies this approach at every stage of drug development, from target discovery to predictive biomarkers. This enables them to rapidly advance new therapeutics into the clinic, ultimately aiming to unlock the curative powers of the immune system. Through strategic collaborations and groundbreaking initiatives, they are at the forefront of personalized immunotherapies and have been recognized for their innovative Drug Intelligence Science (DIS) platform.Generated from the website

Etiometry is a leading provider of clinical decision support technology, focused on enhancing healthcare delivery through its FDA-cleared platform. By integrating deep physiologic insights and automating clinical pathways, Etiometry enables clinicians to make timely decisions that can improve patient outcomes and reduce costs. The platform empowers high-acuity care teams with advanced data aggregation, risk analytics, and quality improvement tools, allowing for personalized patient care and the standardization of workflows. With a proven track record of reducing ICU readmissions and ventilation times, Etiometry is committed to transforming critical care practices in hospitals. Generated from the website

Empress Therapeutics Inc, located in Watertown, MA, is a pioneering biopharmaceutical company that focuses on accelerating drug discovery by harnessing the power of genetics. Their innovative Chemilogics platform utilizes genetic data, artificial intelligence, and machine learning to efficiently generate optimized starting points for drug development. By leveraging co-evolution and synthetic biology, Empress Therapeutics provides access to millions of new chemical compounds, significantly reducing the time required for drug discovery from years to mere months. This approach aims to bring certainty and speed to the development of new medicines sourced from within the human body. Generated from the website